Rosen Law Firm, a global investor rights law firm, announces that it continues to investigate potential securities claims on behalf of shareholders of Impax Laboratories Inc. (NASDAQ:IPXL) resulting from allegations that Impax may have issued materially misleading business information to the investing public. According to news reports, United States prosecutors may file criminal charges against Impax by the end of 2016 for suspected price collusion. On November 3, 2016, Bloomberg reported that the "antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies and about two dozen drugs, according to people familiar with the matter. The grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year, they said." On this news, Impax fell sharply, damaging investors. Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Impax investors. If you purchased shares of Impax please visit the firm's website at http://www.rosenlegal.com/cases-981.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.